CLOS
TEVA icon

Compagnie Lombard Odier SCmA’s Teva Pharmaceuticals TEVA Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,500
Closed -$30.3K – 465
2025
Q3 		$30.3K Sell
1,500
-1,500
-50% -$26.3K ﹤0.01% 372
2025
Q2 		$50.3K Sell
3,000
-500
-14% -$8.07K ﹤0.01% 327
2025
Q1 		$53.8K Buy
+3,500
New +$62.5K ﹤0.01% 349
2022
Q1 		– Sell
-1,000
Closed -$8K – 679
2021
Q4 		$8K Buy
+1,000
New +$9.03K ﹤0.01% 633
2021
Q3 		– Sell
-2,000
Closed -$20K – 677
2021
Q2 		$20K Buy
2,000
+1,200
+150% +$12.7K ﹤0.01% 555
2021
Q1 		$9K Hold
800
– – ﹤0.01% 610
2020
Q4 		$8K Hold
800
– – ﹤0.01% 534
2020
Q3 		$7K Sell
800
-2,560
-76% -$27.1K ﹤0.01% 483
2020
Q2 		$42K Buy
3,360
+2,560
+320% +$29K ﹤0.01% 397
2020
Q1 		$7K Sell
800
-9,000
-92% -$92.2K ﹤0.01% 453
2019
Q4 		$96K Hold
9,800
– – ﹤0.01% 321
2019
Q3 		$68K Buy
9,800
+6,000
+158% +$46K ﹤0.01% 339
2019
Q2 		$34K Sell
3,800
-50,000
-93% -$603K ﹤0.01% 391
2019
Q1 		$844K Hold
53,800
– – 0.03% 161
2018
Q4 		$829K Sell
53,800
-200,000
-79% -$4.1M 0.03% 166
2018
Q3 		$5.47M Buy
253,800
+1,720
+0.7% +$39.9K 0.19% 86
2018
Q2 		$6.13M Hold
252,080
– – 0.23% 80
2018
Q1 		$4.31M Sell
252,080
-292,080
-54% -$5.7M 0.16% 101
2017
Q4 		$10.3M Buy
544,160
+272,080
+100% +$4.09M 0.19% 95
2017
Q3 		$4.79M Buy
272,080
+18,000
+7% +$405K 0.17% 111
2017
Q2 		$8.44M Buy
254,080
+180,000
+243% +$5.57M 0.29% 74
2017
Q1 		$2.38M Buy
74,080
+19,500
+36% +$665K 0.08% 159
2016
Q4 		$1.98M Buy
54,580
+50,843
+1,361% +$2.03M 0.06% 190
2016
Q3 		$172K Sell
3,737
-3,700
-50% -$193K 0.01% 491
2016
Q2 		$373K Buy
7,437
+2,500
+51% +$133K 0.01% 389
2016
Q1 		$264K Sell
4,937
-6,820
-58% -$400K 0.01% 443
2015
Q4 		$772K Sell
11,757
-3,600
-23% -$222K 0.02% 264
2015
Q3 		$867K Buy
15,357
+4,332
+39% +$281K 0.04% 217
2015
Q2 		$652K Buy
11,025
+75
+0.7% +$4.63K 0.02% 267
2015
Q1 		$682K Buy
10,950
+3,770
+53% +$219K 0.03% 271
2014
Q4 		$413K Sell
7,180
-3,397
-32% -$189K 0.02% 293
2014
Q3 		$570K Sell
10,577
-2,477
-19% -$131K 0.02% 289
2014
Q2 		$684K Sell
13,054
-40,033
-75% -$2.05M 0.03% 255
2014
Q1 		$2.81M Sell
53,087
-30,175
-36% -$1.39M 0.12% 112
2013
Q4 		$3.34M Buy
+83,262
New +$3.28M 0.14% 99

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Compagnie Lombard Odier SCmA's TEVA Position: Q4 2025 in Review

Compagnie Lombard Odier SCmA sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 1,500 shares — an estimated $30.3K sold.

Compagnie Lombard Odier SCmA first reported a position in TEVA in Q4 2013 and held it in 35 quarters. The position peaked at $10.3M in Q4 2017. 629 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Compagnie Lombard Odier SCmA reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 1,500 Teva Pharmaceuticals shares in Q4 2025, an estimated $30.3K.
  • Compagnie Lombard Odier SCmA first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 35 quarters.
  • Compagnie Lombard Odier SCmA's Teva Pharmaceuticals position peaked at $10.3M in Q4 2017.
  • 629 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2025, filed 16 Jan 2026.